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Abstract 
The discovery and repurposing of CRISPR/Cas9 has revolutionized the field of genome editing 
and allowed for the development of mouse models with unprecedented simplicity and speed. The 
application of CRISPR/Cas9 in mouse embryonic stem cells represents a highly efficient and well-
established method for generating large-scale conditional knock-in mouse models. This study 
employed a CRISPR/Cas9-mediated gene targeting approach in mouse embryonic stem cells to 
introduce a conditional knock-in construct within intron 11 of the Fbxw7 gene. Fbxw7 is mutated 
in a diverse range of human cancers, including colorectal cancer. As existing mutant Fbxw7 mouse 
models carry null alleles, the aim of this study was to create a mouse model carrying one of the 
commonly occurring point mutations in human cancers (Fbxw7(R482Q)). The construct integrated 
into the genome of mouse embryonic stem cells was a 5.5 kb Cre-dependent conditional knock-in 
that harboured the Fbxw7(R482Q) mutant allele and a cyan fluorescent protein reporter gene. 
Following screening and functional testing of the targeted embryonic stem cells, two confirmed 
clones were microinjected into wild type blastocysts. Subsequently, eight chimeric male mice were 
born from four litters. Two 95% male chimeras are currently breeding with wild type females in 
the hope of achieving germline transmission of the embryonic stem cell derived genes. Successful 
germline transmission will generate heterozygous Fbxw7R482Q mice. Once a breeding population 
is established the Fbxw7R482Q mice will be crossed with Villin-Cre mice to study the role 
Fbxw7(R482Q) in the development of colorectal cancer. 
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1 Introduction 
1.1 Genetically modified mice as human disease models 
Genetically modified (GM) mice are used extensively in biomedical research for modelling human 
disease and studying gene function (Ittner & Delerue, 2015). As a model species, mice act as good 
analogues for most human biological processes since both species share up to 99% of the same 
genes. Mice also have the practical benefits of a short reproductive cycle, large litters, small 
physical size and relatively low maintenance costs. These benefits, in conjunction with the 
increasingly dense map of the mouse genome, the multitude of uniform inbred strains available 
and the establishment of mouse embryonic stem cells (mESCs) makes the laboratory mouse a 
powerful and indispensable model to study the genetic basis of diseases in vivo (Capecchi, 1994; 
Hall et al., 2009; Vandamme, 2015). In addition to studying the mechanistic consequences of 
disease-related genetic alterations, verified mouse models provide an important platform to 
develop new diagnostic and therapeutic strategies to combat these diseases (Peters et al., 2007). 
 
The first GM mice were produced in the early 1980’s by microinjection of plasmids encoding viral 
antigens into the genome of zygotes (Gordon et al., 1980; Palmiter et al., 1982). However, this 
rudimentary method was of no practical use for the detailed study of gene function or for 
developing disease models as integration occurred in a non-targeted manner and without copy 
number control. Pioneering work on DNA repair by homologous recombination (HR) during the 
mid 1980s (Folger et al., 1984) hinted at the prospect that it may be possible to target exogenous 
DNA to specific genomic loci by including a homologous sequence in targeting vectors. These 
findings, along with the isolation of mouse embryonic stem cells (mESCs; Martin, 1981) and 
advancements in the micromanipulation of embryos paved the way for a new strategy to introduce 
site specific modifications into the mouse genome: gene targeting.  
1.2 Classical gene targeting 
Gene targeting is defined as the introduction of site-specific modifications into the genome. Initial 
successes in the mid 1980’s with gene targeting were accomplished by microinjecting DNA 
1 Introduction 
 2 
sequences with high homology to the targeted genomic sequence into cultured mammalian cells 
(Smithies et al., 1985). These experiments utilized a HR-dependent approach, which took 
advantage of the cell’s own DNA repair machinery to replace a targeted genetic locus with an 
introduced DNA sequence. However, the targeting events occurred at very low rates (1 in 3x104 
cells) making it unfeasible to efficiently target zygotes to generate GM mice using this approach 
(Capecchi, 1989). At the time, mESC had been recently isolated (Martin, 1981) and researches 
capitalised on this breakthrough. By using HR-dependent gene targeting in mESCs, scientists 
could transfect, select and screen for clones carrying the alteration of interest. The most common 
selection method was to include a positive selection cassette, such as the neomycin resistance gene 
in targeting vector. After selection in antibiotics and screening, positive mESC clones could be 
expanded and microinjected into WT blastocysts, in the hope that they contribute to the germ cells 
of the resulting chimeric offspring (Behringer et al., 2014; Hughes & Saunders, 2011; Müller, 
1999). Germline competent chimeras could then be bred to produce mice carrying the alteration 
of interest. 
As classical gene targeting in mESCs developed, scientist defined three broad classes of GM mice. 
These are still in use today and are: ‘knock-out’, ‘knock-in’ and ‘conditional’ gene targeted mice. 
In knock-out (KO) mice, a gene is inactivated so that it is no longer functional, whereas in knock-
in (KI) mice, exogenous DNA is added to the genome to modify genetic behaviour. With 
conditional gene targeting a genetic ‘switch’ is introduced that limits KO or KI mutations to be 
active only in specific cells, or at a specific developmental stage (Doyle et al., 2012; Seruggia & 
Montoliu, 2014). These classes of mouse models have contributed greatly to our understanding of 
gene function and genetic basis of disease. However, these classes where established upon classical 
gene targeting protocols in mESCs, which did not allow for the high throughput mouse model 
production that researchers demanded. The technology’s inefficiencies were due to the low 
frequencies with which homologous templates were incorporated into the genome and complicated 
by off-target vector integration, requiring time and labour-intensive screening procedures by 
Southern blotting to ensure correct clone selection. Furthermore, the construction of mouse models 
carrying multiple alterations added substantially more time, cost and effort (Rocha-Martins et al., 
2015). 
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1.3 Double stranded DNA breaks stimulate gene targeting 
A key breakthrough for increasing production efficiency was the realization that double-stranded 
DNA breaks (DSBs) greatly stimulated cellular DNA repair mechanisms (Rouet et al., 1994; Smih 
et al., 1995). All eukaryotic cells efficiently repair DSBs using one of two pathways: non-
homologous end-joining (NHEJ) or a via a form of HR, known as homology directed repair 
(HDR). The former simply joins the broken ends of the DNA, often creating small insertion or 
deletion mutations (indels); the latter uses a homologous DNA template to replace the broken 
region with high fidelity. Thus, the induction of directed DSBs at a genomic locus of interest can 
greatly stimulate gene targeting efficiency. As targeted DSBs in the genome could be introduced 
by nucleases, this method has become known as nuclease-assisted gene targeting (Singh et al., 
2015; Yang, Wang, & Jaenisch, 2014). For KO mice, using the error-prone NHEJ pathway 
frequently results in indel mutations. Indels located within protein-coding exons can cause 
frameshifts resulting in a KO allele. Whilst to achieve KI alleles, donor DNA plasmid or single-
strand oligodeoxynucleotide (ssODN) repair template with homology arms up and downstream of 
the DSB can be used to insert an exogenous DNA sequence via HDR (Chandrasegaran & Carroll, 
2016; Kim & Kim, 2014; Figure 1.1). (Chandrasegaran & Carroll, 2016) 
 
Early nuclease-assisted gene targeting experiments using rare-cutting meganucleases 
demonstrated that DSBs increased the frequency of template integration in mESCs by at least 2 to 
3 orders of magnitude (Rouet et al., 1994). Although this substantial increase in efficiency was a 
significant advance, the practical utility of meganucleases to target any genomic loci at will was 
limited by the long and highly specific DNA recognition sequences (14 to 40 bp) of these enzymes. 
Furthermore, the engineering of meganucleases was extremely challenging for the majority of 
researchers because the DNA recognition sites and cleavage functions of these enzymes are 
intertwined in a single domain (Rocha-Martins et al., 2015; Sander & Joung, 2014). However, the 
possibility of manipulating genomes at will captivated scientist’s attention and the initial 
challenges posed by meganucleases were soon overcome by the development of a new genre of 
truly programmable nucleases; which made it possible to generate DSBs at almost any given 
genomic loci. 
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Figure 1.1 Nuclease-assisted gene targeting. Double strand DNA breaks (DSBs) from site specific 
nucleases could lead to sequence insertion (red box) through homology directed repair (HDR) in the 
presence of a donor DNA plasmid or a single-strand oligodeoxynucleotide (ssODN), both of which 
must contain homology arms. DSBs can also be repaired through non-homologous end joining 
(NHEJ), which frequently leads to small insertions and deletions (indels). Image modified and 
adapted from Kim and Kim (2014). 
1.4 Programmable nucleases systems 
Programmable nucleases have transformed the field of genome editing. This class of nucleases can 
be engineered to bind to a specific nucleotide sequence in the genome and subsequently generate 
a DSBs for gene targeting at a user defined site. Currently, there are three programmable nuclease 
systems used for gene targeting in mice - zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs) and clustered regularly interspaced short palindromic 
repeats/CRISPR-associated protein (CRISPR/Cas) - with the latter quickly gaining prominence 
due to its ease of use. Each of these programmable nuclease systems fundamentally consists of 
two key elements: a DNA recognition domain conferring target specificity and a nuclease domain 
for DNA cleavage (Kim & Kim, 2014; Rocha-Martins et al., 2015). A description of ZFNs, 
TALENs and the now ubiquitously used CRISPR/Cas9 system is provided below. 
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1.4.1 ZFNs (1996) 
A ZFN is comprised of a DNA-binding zinc finger protein (ZFP) domain and a non-specific 
nuclease domain derived from the FokI restriction enzyme. Each zinc-finger recognizes a 3 bp 
DNA sequence in the genome, and 3 to 6 zinc fingers are typically used to generate a single ZFN 
subunit that binds to DNA sequences of 9 to18 bp (Figure 1.2). Importantly, the DNA-binding 
specificities of zinc fingers can be engineered, which is an essential feature for programmable 
nucleases. To achieve DNA cleavage, the modified FokI domain used in ZFNs must be dimerize. 
Thus, two ZFN monomers are required to form an active nuclease and each monomer must bind 
to adjacent half-sites that are separated by spacers of 5 to 7 bp. After binding of the ZFNs the pair 
of FokI nucleases dimerize and generate a DSB with 5′ overhangs. While ZFNs can in theory target 
any genomic sequence, the difficulty of accurately predicting protein conformation and DNA-
protein interactions make ZFN construction a tedious and costly process, involving a substantial 
validation phase prior to application. As such, ZFNs have been restricted to developing GM mouse 
models in only a minority of highly specialized labs (Kim & Kim, 2014; Urnov et al., 2010). 
 
Figure 1.2 A schematic representation of zinc finger nuclease (ZFN) structure. Each ZFN is composed 
of a zinc-finger protein (ZFP) DNA binding domain and a FokI nuclease domain. Image modified 
and adapted from Kim and Kim (2014). 
 
1.4.2 TALENs (2010) 
An analogous but simpler alternative to ZFNs was developed following the deciphering of the 
DNA recognition patterns of transcription activator-like effector proteins (TALEs). The general 
structure of TALENs is similar to that of ZFNs (Figure 1.3). Like ZFNs, TALENs contain the FokI 
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nuclease domain but use a different class of DNA binding domains known as TALEs, which are 
derived from Xanthomonas spp. bacterium. TALEs are composed of tandem arrays of 33 to 35 
amino acid repeats, each of which recognizes a single base-pair. The nucleotide specificity of each 
repeat domain is determined by the two amino acids at positions 12 and 13, which are called repeat 
variable diresidues (RVDs). Although the single base discrimination of TALE modules compared 
to 3 bp recognition in zinc fingers provides less limitations on target selection, the inherently 
repetitive nature of TALE repeats poses a challenge when assembling the DNA molecules to 
encode these proteins. As with ZFNs, TALENs are intrinsically dependent on protein-DNA 
interactions to drive specificity. Due to this dependency, TALENs also require extensive in vitro 
validation as protein conformation often varies depending on the specific context of use. 
Nonetheless, the greater simplicity of TALENs compared to ZFNs has led a broad range of 
laboratories utilizing this technology to generate GM mouse models (Gaj et al., 2013; Gupta & 
Musunuru, 2014; Kim & Kim, 2014). 
 
 
Figure 1.3 A schematic representation of transcription activator-like effector nuclease (TALEN) 
structure. Each TALEN is composed of DNA binding TALE domain and a FokI nuclease domain. 
Each TALE repeat is comprised of 33–35 amino acids and recognizes a single base pair through the 
amino acids at positions 12 and 13, which is called the repeat variable diresidue (RVD; shown in red). 
Image sourced from Kim and Kim (2014). 
 
1.4.3 CRISPR/Cas9 (2012) 
The discovery of bacterial adaptive immune systems known as CRISPR/Cas systems has led to 
the latest set of genome editing tools. These tools have overcome many of the technical challenges 
researchers faced when using ZFNs and TALENs. The RNA-guided CRISPR/Cas system was first 
observed in E. coli in 1987 by its striking genomic structure (Ishino et al., 1987). Evolved as an 
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adaptive immune system in bacteria and archaea, the system uses a set of Cas genes to incorporate 
exogenous DNA into the CRISPR locus, and subsequently transcribe them as RNA templates that 
guide the Cas proteins to cleave invasive DNA or RNA (Horvath & Barrangou, 2010). However, 
the system was not repurposed into a genome editing tool until 2012 when Jinek et al. published 
their seminal paper. Three types of CRISPR/Cas systems have been identified to date, differing in 
their targets as well as mechanisms of action. Type I and III CRISPR systems employ an ensemble 
of Cas genes to carry out RNA processing, targeting, and target site cleavage. By contrast, the type 
II CRISPR/Cas system makes use of a single nuclease, Cas9, to cleave target DNA. Among the 
three types of CRISPR/Cas systems, the type II CRISPR/Cas9, derived from Streptococcus 
pyogenes is presently the most suitable and widely used as a genome editing tool (Chandrasegaran 
& Carroll, 2016; Mojica & Montoliu, 2016; Moore, 2015).  (Jinek et al., 2012) 
 
The S. pyogenes type II CRISPR/Cas9 system consists of a SpCas9 nuclease and two RNAs; 
CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA). SpCas9 is directed to the 
target site by the 20 nt crRNA and the required auxiliary tracrRNA. The crRNA sequence directs 
SpCas9 to the target site by Watson-Crick base-pairing with the target DNA sequence (Cong et 
al., 2013). However, for most genome editing applications the crRNA and tracrRNA are fused to 
form a 102 nt single guide RNA (gRNA). In addition to the crRNA providing specificity, a 
protospacer adjacent motif (PAM), a defined 3 nt sequence at the 3’
 
end of the target DNA 
sequence must be present for DNA cleavage to occur . For SpCas9, the PAM sequence is 5’-NGG, 
which on average occurs every 10 bp in the mouse genome. At an overall structural level, SpCas9 
contains two nuclease domains, HNH and RuvC, each of which cleaves one strand of the target 
DNA (Figure 1.4). In SpCas9, these domains cleave 3 bp upstream from the PAM sequence, 
leaving blunt ends (Hsu et al., 2013; Singh et al., 2015). As the PAM requirements of SpCas9 
limits the potential target sites, CRISPR/Cas9 systems from other species with different PAM 
sequences have been employed for gene targeting mammalian cells (44, 53, 54). For example, the 
Neisseria meningitidis Cas9 PAM has been reported to be 5’-NNNNGATT (Hou et al., 2013). 
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Figure 1.4 A schematic representation of Streptococcus pyogenes CRISPR-associated protein-9 
(SpCas9) structure, which is programmed with a single guide RNA (gRNA). gRNA comprises a site 
specific CRISPR RNA (crRNA; green) and an auxiliary trans-activating crRNA (tracrRNA; orange). 
After the gRNA and SpCas9 bind to the target site, the recognition (REC) and nuclease lobes (NUC) 
undergo rotation to fully enclose the DNA target sequence. Two nuclease domains (RuvC and HNH) 
each cut one DNA strand 3 bp upstream from the protospacer adjacent motif (PAM) to generate a 
double strand DNA break (DSB). Image sourced from ozbiosciences.com. 
 
In contrast to ZFNs and TALENs, which require the design of proteins that are encoded by large 
repetitive DNA segments (500 to 1500 bp) for each new target site, CRISPR/Cas9 can be easily 
adapted to target almost any genomic sequence by simple exchanging the 20 nt crRNA. This can 
be easily accomplished by subcloning the 20 nt sequence into a gRNA expression plasmid. The 
SpCas9 protein component remains unchanged, alleviating the need for complex protein 
engineering. Like previous programmable nucleases, CRISPR/Cas9 provides highly efficient and 
precise genome editing capabilities in mice (Gupta & Musunuru, 2014).  CRISPR/Cas9 induced 
mutation rates of up to 78% have been obtained in mice (Fujii et al., 2013; Yang, Wang, Shivalila, 
et al., 2014). However, the most significant advantage that CRISPR/Cas9 offers over ZFNs and 
TALENs is that it uses reagents that are simple, cheap, and quick to design and generate (Gupta & 
Musunuru, 2014). Furthermore, since the repurposing of CRISPR/Cas9 as a genome editing tool 
several technological innovations have evolved from the technology. These include: multiplexing 
mutations with several gRNAs in a single step (Cong et al., 2013), the development of a paired 
Cas9 ‘nickase’ system (Shen et al., 2014), dimerizing of dCas9 (dead Cas9; catalytically inactive) 
system fused with a FokI endonuclease (Tsai et al., 2014), and adding a DNA-binding domain for 
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improved target specificity (Bolukbasi et al., 2015). With these successive innovations, the 
CRISPR/Cas9 system has become widely adapted for a multitude of genome editing applications.  
1.5 Gene targeting with CRISPR/Cas9 
The efficiency of CRISPR/Cas9 as a genome editing tool has allowed for gene targeting by direct 
microinjection into zygotes. For the development of KO and simple KI mouse models this 
alleviates the cost and labour required with mESC technology (Singh et al., 2015). Although ZFNs 
and TALENs also have this ability. The standard method for generating KO alleles using 
CRISPR/Cas9 is co-injection of Cas9 mRNA and gRNA into the pronucleus and/or cytoplasm of 
mouse zygotes. Alternatively, pronuclear injection of recombinant Cas9 protein in complex with 
gRNA (Ribonucleoprotein (RNP)) has also proven to be very effective for generating KO alleles 
(Chen et al., 2016; Williams et al., 2016; Table 1.1) In both cases, the gRNA is directed to a protein 
coding exon in the target gene. Once a DSB is induced at the target site it is favourably repaired 
by NHEJ, which is the most active repair pathway in mammalian cells. The error prone NHEJ 
pathway frequently results to small indels that ideally cause a frameshift in the protein-coding exon 
and consequently a loss-of-function mutation within the targeted gene (Gaj et al., 2013). Targeted 
zygotes are then transferred into foster mothers to develop in KO mouse models. 
 
The production of simple KI mouse models by direct microinjection is similar to KO model 
production but requires the inclusion of a repair template. In addition to Cas9 (mRNA or RNP) 
and gRNA, a ssODN template is also required to induce the cell to repair the DSB by HDR. One 
important consideration in ssODN design is ensure the gRNA target site or PAM is altered after 
integration of the targeting vector by HDR. This will prevent recurrent cleavage of the target site, 
which could lead to undesirable mutations (Singh et al., 2015; Williams et al., 2016). Scientists 
have been consistently successful in generating CRISPR/Cas9-mediated KI alleles in zygotes with 
ssODN template lengths ranging from 100 to 200bp in total, with at least 40 bp homology arms 
on either side of your intended DSB (Rappaport & Johnson, 2014; Skarnes, 2015). Recently, 
Yoshimi et al. (2016) successfully achieved a 1kb KI using a long synthetic ssODN but this 
technique requires further investigation before widespread application is seen.  
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Researchers have embraced direct CRISPR/Cas9 microinjection of zygotes for generating KO and 
rudimentary KI mouse models. Although direct zygote injection is effective for simple KI alleles, 
the generation of larger more complexed KI alleles requires HDR with a donor DNA plasmid, 
which is difficult to produce by direct zygote injection (Skarnes, 2015). In a study by Yang, Wang, 
and Jaenisch (2014), they reported that only 10 to 30% of zygotes co-injected with CRISPR/Cas9 
and donor plasmids carried the desired modification. As such, the ‘gold standard’ for generating 
large-scale KI mouse models remains the well-established mESC technology (Chen et al., 2016). 
With this approach a CRISPR expression plasmid (Table 1.1) and donor DNA plasmid is 
electroporated into mESCs. Donor plasmids typically consist of homology arms (each >800 bp), 
the KI cassette of interest and selection markers, such as antibiotics resistance or fluorescent 
proteins for identifying successfully transfected cells. Following selection, researchers can screen 
and expand positive clones for injection into WT blastocysts to generate chimeric offspring for 
germline transmission (Singh et al., 2015; Wang et al., 2015). Although more laborious and costly 
than direct gene targeting in mouse zygotes, the proven ability of mESC technology to handle 
complex KI alleles is yet to be rivalled by direct zygote microinjection (Skarnes, 2015).  
 
Table 1.1 Components and applications of CRISPR/Cas9 expression systems used for generating 
genetically modified mouse models. 
Expression system Components of system Application 
CRISPR expression 
plasmid 
Promoter driving Cas9 expression can 
be constitutive or inducible. U6 
promoter is typically used for 
expressing gRNA in the same 
plasmid. May contain a selection 
marker (e.g. neomycin resistance) to 
generate stable cell lines. 
Transient expression of Cas9 and 
gRNA in mammalian cells which 
can be transfected via 
electroporation at high efficiency. 
Commonly used for gene targeting 
in mESCs. 
Cas9 mRNA and gRNA Plasmids containing gRNA and Cas9 
are used in in vitro transcription 
reactions to generate Cas9 mRNA 
and gRNA, then delivered to target 
cells. 
 
Transient expression of 
CRISPR/Cas9 components, 
expression decreases as RNA is 
degraded within the cell. Typically 
microinjected directly into zygotes. 
Ribonucleoprotein(RNP) Purified Cas9 protein and in vitro 
transcribed gRNA are combined to 
form a Cas9/gRNA complex and 
delivered to cells. 
Transfection of cells via 
microinjection or electroporation. 
Instant CRISPR/Cas9 activity, 
with expression decreasing as RNP 
is degraded within the cell. 
Note:1) CRISPR/Cas9 can also be expressed via viral transduction systems, however, these systems are not currently 
used for generating GM mice. 
         2) Information within this table was sourced from: Behringer et al. (2014), Chen et al. (2016) and Sato et al. 
(2016) 
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1.6 Conditional gene targeting 
Conventional KO and KI gene targeting strategies are effective for developing a wide variety of 
GM mouse models. However, the role of many mutations cannot be investigated due to early lethal 
phenotype preventing the study of its later roles or the phenotype affects multiple tissues, 
preventing the detailed study of its function in a particular tissue or organ. To overcome this issue, 
the application of site specific recombinase systems has made it possible to ‘switch on’ mutations 
in specific cells or at a specific developmental stage (Bayascas et al., 2006; Kwan, 2002; Tahimic 
et al., 2013). Site-specific recombinase systems consist of two basic elements: the recombinase 
enzyme and a DNA sequence that is specifically recognized by that particular recombinase. 
Recognition is through a consensus sequence and the recombinase catalyses recombination 
between two of its recognition sites to bring about genome modification. Currently, there are two 
recombinase systems used in mouse gene targeting experiments: Cre-loxP and Flp-FRT systems 
(Kwan, 2002). 
 
The Cre/loxP system, derived from the P1 bacteriophage and the Flp-FRT system from 
Saccharomyces cerevisiae are used for generating conditional alleles in mouse models. Each of 
these recombinases (Cre or Flp) recognizes a 34-bp consensus sequence consisting of two 13 bp 
palindromic sequences (Cre or Flp recognition sites) and an 8 bp non-palindromic core that is 
responsible for the directional nature of the recognition site (loxP or FRT; Figure 1.5a; Kwan, 
2002). Flp/FRT is less frequently employed due to its lower efficiency (Meyers et al., 1998). 
Therefore, for ease and clarity of explanation, herein, the focus will be on widely employed 
Cre/loxP system; although Flp/FRT can be used in many of the same strategies. Within Figure 
1.5b, it can be seen that two loxP sites in the same direction will result in excision of the intervening 
DNA by Cre induced recombination, leaving one intact loxP site. In contrast, where two loxP sites 
are in the opposing directions, the recombinase will invert the intervening piece of DNA. The  
34 bp loxP recognition site is very unlikely to occur at random in the mouse genome, yet is small 
enough to be considered a ‘neutral’ sequence when integrated into the mouse genome (Kwan, 
2002).  
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Figure 1.5 Site-specific recombinase systems (a) Structure and sequence of the loxP and FRT 
recombinase recognition sites. Each site consists of two 13 bp inverted repeats flanking an 
asymmetric 8 bp core region that defines the directionality of the recognition site. (b) Digram of a 
deletion and inversion by Cre/loxP and Flp/FRT mediated recombination. Image was modified and 
adapted from Kwan (2002). 
 
As targeting vectors for inserting Cre/loxP conditional alleles are very large, frequently exceeding 
5 kb to include the intervening DNA sequence, they typically require the use mESCs and donor 
plasmids for efficient construct integration (Tahimic et al., 2013). To overcome the costly and 
laborious requirements of using mESCs for generating conditional mutant mice, Yang, Wang, 
Shivalila, et al. (2014) developed a ‘one-step’ CRISPR/Cas9-mediated method for generating 
flanked by loxP (floxed) alleles directly in mouse zygotes. Their method involves the simultaneous 
injection of Cas9 mRNA, two gRNAs targeted at desired loxP locations, and two corresponding 
ssODN templates encoding loxP sites and 60 nt homology arms surrounding the DSB sites. Using 
this strategy, the genome is cut twice at different genomic loci and separate loxP sites are integrated 
into the DSBs via HDR with ssODNs. Although this system reduces the cost, time and number of 
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mice required for generating conditionally mutant mice, to date the author is not aware of any other 
publications or reports of studies that have utilized this ‘one-step’ CRISPR/Cas9-mediated 
approach for generating conditional alleles directly in mouse zygotes. At present, it seems 
researchers are continuing to employ the well-established protocols of mESC technology to 
generate Cre/loxP conditional alleles.  
 
There are three common strategies employed for generating conditional KI mouse models. These 
are: the ‘heterozygous’, ‘minigene’ and ‘inversion’ methods (Figure 1.6). In the heterozygous 
method, a mouse is generated that has one allele which comprises a floxed WT exon, whereas the 
second allele contains the KI mutant exon and is not floxed. In tissues that express Cre, the WT 
exon will be excised leaving only expression of the KI mutant allele (Figure 1.6a). The 
disadvantage of this method is that in non-Cre-expressing tissue both the mutant and WT protein 
is expressed. To avoid expression of mutant protein in non-Cre-expressing tissues, the minigene 
method can be employed. In this method, an allele is constructed in such a way that in the absence 
of Cre, an artificial version of the wild gene is expressed. This wild gene consists of an intronless 
minigene and STOP casette that are floxed. The construct is designed so that Cre-mediated 
recombination leads to the excision of the floxed minigene and STOP cassette, resulting in the 
expression of the KI mutant allele (Figure 1.6b). A third approach, called the inversion method, 
relies upon opposing orientations of loxP sequences. In the inversion method, the KI exon is cloned 
in an antiparallel orientation after the WT exon, and the WT and inverted KI exons are floxed 
(Figure 1.6c). In the absence of Cre, the WT exon will be expressed and the sequence within the 
inverted KI exon should be spliced-out of the pre-mRNA. In the presence of Cre recombinase, 
DNA inversion would result in the KI exon being expressed rather than the WT (Bayascas et al., 
2006; Tahimic et al., 2013). These three methods have given investigator great flexibility in 
constructing conditional alleles. 
 
Once a conditional gene targeting system has been integrated and validated in a mouse genome, 
the investigator must decide how and when to ‘switch on’ the mutation. To switch on a Cre/loxP 
conditional mutation requires two reagents, typically in the form of two different GM mouse lines. 
One mouse line expresses the Cre recombinase under the control of a cell specific or 
developmental specific promoter. The other line carries the conditional allele. After crossing the 
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two GM mouse lines, cells expressing Cre recombinase in the offspring will recombine the loxP 
sites and switch on the mutation (Bayascas et al., 2006). An alternative method for temporally 
controlling conditional alleles is to introduce a tamoxifen-inducible Cre recombinase allele into 
the conditional mouse model. Using this strategy, Cre recombinase is not expressed until 
tamoxifen is applied topically or by injection into the mouse (Bayascas et al., 2006; Tahimic et al., 
2013). By controlling when and where mutations are activated in a mouse model enables 
investigators to study the mechanistic consequences of genetic alterations in a particular tissue 
and/or at a specific stage of development. 
 
 
Figure 1.6 Conditional knock in (KI) strategies: (a) heterozygous method, (b) minigene 
method and (c) inversion method. A hypothetical gene consisting of four exons is depicted. 
The white boxes are wild type (WT) exons and the black boxes represent a mutant exon 2. 
The black arrows indicate the orientation of loxP sites. The minigene (MG) cassette is 
depicted as a gray box and corresponds to WT exons 2– 4 followed by a polyadenylation 
transcription termination signal (A). Cre-Rec is Cre-mediated recombination. IC is inversion 
cassette. Image modified and adapted from Bayascas et al. (2006). 
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1.7 Aim 
This study aims to generate a GM mouse model with a conditional KI missense point mutation in 
the F-box and WD40 repeat domain-containing 7 gene (Fbxw7). Fbxw7 has pivotal roles in cell 
division, growth, and differentiation by degrading several proteins, including c-Myc, Notch1, 
Notch4, c-Jun, and cyclin E (Nakayama & Nakayama, 2006). Given that most of these proteins 
targeted by Fbxw7 for degradation are proto-oncoproteins, Fbxw7 has been proposed to function 
as a tumour suppressor gene (Davis et al., 2014; Davis et al., 2011). Indeed, Fbxw7 is commonly 
mutated in a diverse range of tumors, including colorectal, breast and lung cancer. In a previous 
study, the conditional deletion of both alleles of Fbxw7 in the intestine of mice was shown to 
induce the development of adenomas that accumulate several Fbxw7 substrates, including both c-
Myc and Notch1 (Babaei-Jadidi et al., 2011). As existing mutant Fbxw7 mouse models carry null 
alleles, this study aims to create a mouse model carrying one of the commonly occurring point 
mutations in human cancers (Fbxw7(R482Q); Davis et al., 2011). Fbxw7(R482Q) is a guanine to 
adenine mutation within exon 12 that results in an arginine to glutamine substitution in the 
substrate recognition domain of Fbxw7.  
 
To generate the Fbxw7R482Q mouse model, a CRISPR/Cas9-assited gene targeting strategy will be 
employed to generate mESC clones harboring a 5.5 kb Cre-dependent conditional KI construct. 
The KI construct contains a floxed WT Fbxw7 minigene and STOP cassette followed by the 
Fbxw7(R482Q) mutant allele and cyan fluorescent protein (CFP) reporter gene. The system allows 
for Cre-dependent conditional expression of the Fbxw7(R482Q) mutant allele and CFP from the 
natural promoter. By including a CFP reporter gene it permits investigators to visually identify 
cells expressing of the mutant Fbxw7(R482Q) allele. Confirmed mESC clones will be injected 
into WT blastocysts to develop into chimeric mice for further breeding. In developing the 
Fbxw7R482Q mouse model, this reported will highlight key methodologies and findings for 
generating conditional KI alleles using CRISPR/Cas9 in mESCs. Methods and findings will 
include: gRNA design and validation, subcloning of gRNA into a CRISPR expression plasmid, 
the transfection and screening of mESCs, functional testing of Cre-dependent conditional KI 
alleles, blastocyst microinjection and uterine transfer, and finally discuss future breeding plans for 
germline competent chimeras. Once a breeding population is established the Fbxw7R482Q mouse 
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model will be used by the Tomlinson group at the Wellcome Trust Centre for Human Genetics 
(WTCHG) to study the role of the Fbxw7(R482Q) in the development of colorectal cancer. 
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2 Materials 
2.1 Buffers and solutions 
1% agarose gel 
Components Amount Company 
Agarose 1.5g Sigma-Aldrich, US 
Ethidium Bromide 3µl Sigma-Aldrich, US 
TAE (1X) 150ml Severn Biotech, UK 
 
PCR reaction mix (20µl) 
Components Amount Company 
Buffer (10x) 2µl Bioline, UK 
MgCl2 (10µM) 0.6µl Bioline, UK 
Primer 1 (10µM) 1µl Invitrogen, US 
Sigma-Aldrich, US 
Primer 2 (10µM) 1µl Invitrogen, US 
Sigma-Aldrich, US 
dNTPs (10µM) 0.4µl Bioline, UK 
Taq Polymerase 0.2µl Bioline, UK 
Q Solution 4µl Qiagen, GE 
dH2O 9.8µl WTCHG, UK 
Genomic DNA 1µl N/A 
 
Long Amplification PCR reaction mix (20µl) 
Components Amount Company 
Buffer (10x) 4µl New England Biolabs, US 
Primer 1 (10µM) 0.8µl Invitrogen, US 
Sigma-Aldrich, US 
Primer 2 (10µM) 0.8µl Invitrogen, US 
Sigma-Aldrich, US 
dNTPs (10µM) 0.6µl WTCHG, UK 
Long Amp. Taq. Pol. 0.7µl New England Biolabs, US 
dH20 12.1µl WTCHG, UK 
Genomic DNA 1µl N/A 
 
0.1% TE buffer 
Components Amount Company 
Tris HCl pH7.4 (1M) 100µl Sigma-Aldrich, US 
EDTA (0.5M) 20µl Sigma-Aldrich, US 
dH2O 99.7ml WTCHG, UK 
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Additional buffers and solutions 
Buffers and solutions Company 
Gel loading dye (6x) New England Biolabs, US 
Gel ladders (100bp and 1kb) New England Biolabs, US 
BbsI enzyme  New England Biolabs, US 
T4 DNA Ligase New England Biolabs, US 
T4 Ligase Buffer New England Biolabs, US 
ATP 10mM WTCHG, UK 
Plasmid safe ATP dependent nuclease Epicentre, US 
Cutsmart buffer New England Biolabs, US 
Lithium chloride (8M) Sigma-Aldrich, US 
Isopropanol Sigma-Aldrich, US 
Ethanol Sigma-Aldrich, US 
Hind III - HF New England Biolabs, US 
2.2 Bacteria and cell culture media and reagents 
Melanoma cell culture media 
Components Amount Company 
IMEM 45ml Sigma-Aldrich, US 
FCS 5ml Thermo Fisher, US 
L-glutamine (200mM) 1ml Sigma-Aldrich, US 
 
With penicillin/streptomycin selection: 
 
Penicillin/Streptomycin (10,000 
U/ml) 
500µl in 50ml of B16F10 
media 
Gibco, US 
 
Embryonic stem cell (mESC) culture media 
Components Amount Company 
KnockOut DMEM (1X) 500ml Thermo Fisher, US 
FCS 50ml Thermo Fisher, US 
Penicillin/Streptomycin (10,000 
U/ml) 
6ml Gibco, US 
MEM Non-essential Amino 
acids (100x) 
6ml Sigma-Aldrich, US 
1000x βME 500µl Sigma-Aldrich, US 
LIF 60µl Millipore, UK 
 
With puromycin selection: 
Puromycin (1mg/µl) 30µl in 50ml of JM8 media	 Sigma-Aldrich, US 
 
With neomycin selection: 
G418 (350ng/µl) 30µl in 50ml of JM8 media Sigma-Aldrich, US 
 
With neomycin half selection: 
G418 (350ng/µl) 15µl in 50ml of JM8 media Sigma-Aldrich, US 
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Trypsin 2X + G 
Components Amount Company 
EDTA (0.5M) 0.1g Sigma-Aldrich, US 
D-Glucose 0.5g Sigma-Aldrich, US 
Chicken Serum 5ml Thermo Fisher, US 
Trypsin (2.5%) 20ml Thermo Fisher, US 
 
Freezing media for embryonic stem cells 
Components Percentage Company 
JM8 ES cell media 40% WTCHG, UK 
FCS 40% Thermo Fisher, US 
DMSO 20% Sigma-Aldrich, US 
 
Lysis buffer for cell culture 
Components Amount Company 
SDS (0.1%) 1ml Sigma-Aldrich, US 
Proteinase K (20mg/ml) 20µl Bioline, UK 
RNase A (10mg/ml) 4µl Sigma-Aldrich, US 
 
Additional reagents 
Reagents Company 
Chorionic gonadotropin human (hCG) Sigma-Aldrich, US 
Dulbecco’s phosphate buffered saline Sigma-Aldrich, US 
Fugene HD Transfection Reagent Promega, US 
KSOM Thermo Fisher, US 
LB Agar Sigma-Aldrich, US 
LB Broth Sigma-Aldrich, US 
M2 media with HEPES Sigma-Aldrich, US 
Opti-MEM Thermo Fisher, US 
Pregnant mare's serum gonadotropin (PMSG) Sigma-Aldrich, US	
Purified mineral oil Sigma-Aldrich, US 
TAT-Cre Recombinase (207uM) Millipore, UK 
Trypsin-EDTA Sigma-Aldrich, US 
Vetergesic (buprenorphine) Sogeval, UK 
Water for embryo transfer Sigma-Aldrich, US 
2.3 Bacteria, cells and animals  
Bacteria Company 
ElectroSHOX Escherichia coli Bioline, US 
 
Murine cell line Common name 
JM8.F6 male embryonic stem cells Mouse embryonic stem cells (mESCs) 
B16F10 melanocytes Mouse melanoma cells  
DR4 Murine embryonic fibroblasts Murine embryonic fibroblasts (MEFs) 
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Mouse strain Common name Utility 
B6(Cg)-Tyrc-2J/J Bl6-Albino Blastocyst harvesting 
Chimeric breeding program 
CD1  CD1 Foster mothers 
2.4 Primers 
gRNA primers were designed using the CRISPOR online tool (http://crispor.tefor.net), which was 
developed by Haeussler et al. (2016). Critically, a gRNA was selected with a target site present in 
the natural WT Fbxw7 allele but absent in the donor DNA plasmid (Fbxw7 donor plasmid). 
Overhangs were added to the gRNA primers to accommodate for BbsI restriction sites that were 
used for ligating the annealed gRNA primers into the CRISPR expression plasmid. BbsI specific 
overhangs are shown below in red on annealed gRNA primers.	
 
      CRISPR primer forward: 5’-CACCGGGACCCTGGTTCCACCTCA-3’ 
      CRISPR primer reserve:     3’-CCCTGGGACCAAGGTGGAGTCAAA-5’ 
 
All other primers were designed using Primer3 (version 0.4.0) software. All primers were 
purchased from either Invitrogen or Sigma-Aldrich. Working concentrations for all primers was 
10µM. 
 
gRNA primers  
Primer Orientation Sequence 
gRNA-F Forward 5’-CACCGGGACCCTGGTTCCACCTCA-3’ 
gRNA-R Reverse 3’-AAACTGAGGTGGAACCAGGGTCCC-5’ 
 
Primers for sequencing 
Primer Orientation Sequence 
U6-F Forward 5’-AATCATGGGAAATAGCCTC-3’ 
Fbxw7-F Forward 5’-TGAGCACGTGTCTGAAACTGA-3’ 
 
Primers for screening mutagenesis 
Primer pair (PP) Orientation Sequence 
PP1 Forward 5’-TGAGCACGTGTCTGAAACTGA-3’ 
 Reverse 5’-GTAAACACTGGCCGGTCTCA-3’ 
PP2 Forward 5’-TAGGCATAATATTGAGGATGGAAGC-3’ 
 Reverse 5’-TGGTCATGTCCACTATGGACTC-3’ 
PP3 Forward 5’-GGAGAGCTGTGGTATGTGGC-3’ 
 Reverse 5’-CCTTGATGCCATTCTTCTGC-3’ 
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2.5 Plasmids 
This section lists all plasmids used in this study. An overview of the functional features within 
each plasmid can be found in Appendix A. The concentration and quality of the plasmid 
purifications are shown in the NanoDrop™ spectrophotometry readings in Appendix B. 
 
2.5.1 CRISPR expression plasmid 
The CRISPR expression plasmid was purchased from the Addgene repository, where its official 
name is pX330-U6-Chimeric_BB-CBh-hSpCas9 (Plasmid #42230). It is a human codon-
optimized SpCas9 and gRNA expression plasmid. The plasmid was initially designed by Cong et 
al. (2013) and was a gift to the Addgene repository from Dr Feng Zhang. After acquiring the 
plasmid, Dr Ben Davies at WTCHG modified the plasmid by adding a puromycin resistance 
cassette. 
 
Figure 2.1 CRISPR expression plasmid map (map was modified and adapted from addgene.org). The 
functional role of each plasmid feature is described in Appendix A. 
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2.5.2 Fbxw7 donor plasmid 
The Fbxw7 donor plasmid was designed and constructed by the Tomlinson group at the WTCHG. 
The official name of the plasmid is pMA-mFbxw7(R482Q)-CFP. It is a donor DNA plasmid 
targeted at inserting Cre-dependent conditional KI point mutation (R482Q) within intron 11 of 
Fbxw7. The missense point mutation (R482Q) is within exon 12. A CFP reporter gene is included 
to tract expression of the mutant Fbxw7(R482Q) allele. The plasmid also has carries neomycin 
resistance gene for positive selection and diphtheria toxin A cassette for negative selection. 
 
 
Figure 2.2 Fbxw7 donor plasmid map (map was sourced from the Tomlinson group at the WTCHG). 
The functional role of each plasmid feature is described in Appendix A. 
 
2.5.3 GFP expression plasmid 
The green fluorescent protein (GFP) expression plasmid was constructed by Dr Ben Davies at the 
WTCHG. The official name of the plasmid is pCX-eGFP. It is frequently used as a control to 
assess plasmid transfection efficiency in mammalian cells. It sole role is to express GFP. 
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Figure 2.3 GFP expression plasmid map (map was sourced from Dr Ben Davies at the WTCHG). The 
functional role of each plasmid feature is described in Appendix A. 
 
2.6 Kits 
Kit Company 
GeneJET Plasmid Midiprep Kit Thermo Fisher, US 
Mix2Seq Kit Eurofins, GE 
Neon Transfection Kit Invitrogen, US 
2.7 Software 
Software Company 
CRISPOR Tefor Infrastructure, FRA 
Endnote X7 Thomson Reuters, US 
Microsoft Office Microsoft, US 
SnapGene GSL Biotech LLC, US 
TIDE analysis Netherlands Cancer Institute, NE 
USCS Genome Browser University of California, US 
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2.8 Equipment and consumables 
Equipment and consumables Company 
Cell imaging system Biorad, US 
Centrifuge and PCR tubes VMR, US 
Centrifuges Thermo Fisher, US 
Electrophoresis gel chambers Hoefer, US 
Gel imaging system Biorad, US 
Heating block Jencons, US 
Incubator New Brunswick, GE 
Micromanipulator Eppendorf, GE 
Microscope Nikon, JAP 
Mr Frosty Freezing Container Thermo Fisher, US 
NanoDrop™ spectrophotometer Thermo Fisher, US 
Neon electroporation system Invitrogen, US 
Pipettes Gilson, US 
Thermocycler VWR, US 
Thermomixer Eppendorf, GE 
Tissue culture plates and flasks Cellstar, US 
Vortex Scientific Industries, US 
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3 Methods 
3.1 Molecular biology techniques 
3.1.1 Annealing gRNA primers  
To anneal the gRNA primers, the reagents listed below were added to a 1.5ml microcentrifuge 
tube and incubated at 100°C for 5 mins in a heating block. The heating block was then turned off 
and tubes were left to cool to room temperature in the heating block. 
 
Reagents Volume (µl) 
gRNA-F primer (100µM) 2 
gRNA-R primer (100µM) 2 
TE Buffer pH 8.0 (0.1%) 16 
 
3.1.2 Subcloning of gRNA primers into CRISPR expression plasmid 
The annealed gRNA primers were subcloned into the CRISPR expression plasmid using Bbsi 
restriction sites (Figure 4.2). All reagents listed below were added to a 0.2ml PCR tube.  
 
Reagents Volume (µl) 
CRISPR expression plasmid (150ng/µl) 1 
Annealed gRNA Primers 1 
BbsI 1 
T4 DNA ligase	 1	
T4 Ligase Buffer (10x)	 2	
dH2O	 14	
 
The mixture was then and run on a thermocycler with the following parameters. 
 
   Step Temperature Time (mins) 
   1 37°C 5 
   2 16°C 10 
Repeat steps 1 through 2 for 9 additional cycles 
   4 50°C 5 
   5 80°C 5 
   6 4°C Infinite 
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Once the reaction had cooled to 4°C the mixture was treated with plasmid safe nuclease by adding 
the reagents listed below into the 0.2ml PCR tube. The mixture was then incubated in a 
thermocycler at 37°C for 1 hour before storing at -20°C until required.  
 
Reagents Volume (µl) 
Cloned CRISPR expression plasmid plasmid 20 
10mM ATP 1 
Plasmid Safe Nuclease 1 
 
3.1.3 Amplification and purification of CRISPR expression plasmid 
To amplify the cloned CRISPR (cCRISPR) expression plasmid, 500ng of cCRISPR expression 
plasmid was added to 100µl of ElectroSHOX E. coli in 1.5ml microcentrifuge tube. After 20 mins 
on ice, the tube was heat shocked at 42°C for 90 secs and immediately placed back on ice for a 
further 5 mins. The culture was then plated onto a 10cm LB agar plate with 100mg/ml of ampicillin 
and grown for 24 hours at 37°C. The following day one isolated bacterial colon was picked into 
50ml LB broth with 100mg/ml ampicillin and incubated overnight at 37°C on a rocking platform. 
The plasmid was then extracted and purified using GeneJET Plasmid Midiprep Kit following the 
manufacturer’s instructions. 
 
3.1.4 Validated cCRISPR expression plasmid 
Two assays were undertaken to confirm successful subcloning of the annealed gRNA primers into 
the cCRISPR plasmid. Firstly, 2µl of the purified cCRISPR plasmid was digested with BbsI and 
HindIII restriction enzymes. The plasmid digest was then run on a 1% agarose gel electrophoresis 
(GE) and imaged. Secondly, the cCRISPR plasmid was sent for Sanger sequencing using the  
U6-F primer. 
 
3.1.5 Lysis and DNA extraction from cells 
Confluent cells were lysed with Lysis Buffer for cell culture using an appropriate amount for plate 
size and incubated at 37°C for 16 hours. Lithium chloride and isopropanol DNA purification was 
then performed on the lysate. 1/10th volume of lithium chloride (8M) and 1 volume of isopropanol 
were added to the plate and placed on a rocking platform for 20 mins. The plate was the centrifuged 
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at 2500rpm for 20 mins and the supernatant discarded. The plate was the washed twice with 70% 
ethanol and the resulting DNA pellet was resuspended in an appropriate amount of 0.1% TE buffer. 
 
3.1.6 PCR protocols 
PCR products of <1000bp were amplified using the PCR protocol shown below. The lid 
temperature of the thermocycler was set at 111°C. 
 
  Step Temperature Time 
  1 95°C 10 mins (hot start) 
  2 94°C 1 mins 
  3 57°C 1 mins 
  4 72°C 30 secs 
Repeat steps 2 through 4 for 31 additional cycles 
  5 72°C 10 mins 
  6 4°C Infinite 
 
PCR products of >1000bp were amplified using the PCR protocol shown below. The lid 
temperature of the thermocycler was set at 112°C. 
 
  Step Temperature Time 
  1 94°C 2 mins 30 secs (hot start) 
  2 94°C 30 secs 
  3 60°C 40 secs 
  4 65°C 50 secs per 1000bp 
Repeat steps 2 through 4 for 31 additional cycles 
  5 65°C 10 mins 
  6 4°C Infinite 
 
3.1.7 DNA gel electrophoresis 
All PCR products <1000bp were run in 2% agarose gel made from 1% TAE, whilst products 
>1000bp were run in 1% agarose gel made with 1% TAE. Gel chambers were filled with 1% TAE 
buffer and operated at 120V and 300mA. Time varied appropriate to the size of PCR product and 
resolution required. 
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3.1.8 Sanger sequencing 
All Sanger sequencing was performed by Eurofins Germany using their Mix2Seq kit and following 
the company’s preparation guidelines. 
3.2 Cell culture protocols 
All cells were cultured at 37°C with 5% CO2. Culture media was refreshed daily. A workflow of 
both the melanocyte and mESC culturing procedures used in this study can be found in  
Appendix C.  
 
3.2.1 Mouse melanoma cell culture 
B16F10 melanoma cells were thawed and expanded in melanoma cell culture media with 
penicillin/streptomycin up to a T25 culture flask. Passaging of melanoma cells involved washing 
twice with PBS before adding Trypsin-EDTA and incubating for 5 mins at 37°C. Trypsin was then 
neutralised with an appropriate amount of cell culture media. 
 
Lipofection of melanoma cells 
At 70% confluence, media was changed to melanoma cell culture media with no 
penicillin/streptomycin in preparation for lipofection. For lipofection, 550ng of cCRISPR 
expression plasmid was mixed with 26µl of Opti-MEM media and 1.7µl of Fugene HD reagent in 
a 1.5ml microcentrifuge tube. The mixture was then incubated at room temperature for 10 mins. 
550ng of GFP expression plasmid was prepared in identical fashion. 25µl of each incubated 
complex was added to separate wells in 24 well plate (WP) with 70% confluent melanoma cells. 
Cells were then incubated for 24 hours before changing back to melanoma cell culture media with 
penicillin/streptomycin. 
 
Analysis of transfected melanoma cells 
Once confluent, melanoma cells lipofected with GFP expression plasmid were assessed for GFP 
expression under fluorescence microscopy using a fluorescein isothiocyanate (FITC) filter. Cells 
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transfected with cCRISPR expression plasmid and the non-transfected control melanoma cells 
were lysed and DNA was extracted. Extracted DNA was PCR amplified across the CRISPR/Cas9 
target site using primer pair 1 (PP1). The PCR product were sent for Sanger sequencing using PP1-
Forward primer. A tracking of indels by decomposition (TIDE) analysis was then undertaken using 
the quantitative trace data from the two Sanger sequencing reactions. The TIDE analysis was 
performed using the Netherlands Cancer Institute TIDE analysis web tool (http://tide-
calculator.nki.nl) with default settings. This free online tool was developed by Brinkman et al. 
(2014). 
 
3.2.2 Embryonic stem cell culture 
JM8.F6 mESCs were thawed and expanded in ESC culture media on MEF feeder layer up to T75 
culture flask. Passaging of mESCs involved aspirating off media and washing twice with PBS 
before adding trypsin 2X+G and incubating for 8 mins at 37°C. Trypsin was then neutralised with 
an appropriate amount of cell culture media. 
 
Electroporation of embryonic stem cell 
In preparation for electroporation, mESCs in T75 flask were passaged and resuspended at  
1 x 106 cells per 100µl in Buffer R from the Neon Transfection Kit. 100µl of mESC suspension 
and 5ug of both cCRISPR expression plasmid and Fbxw7 donor plasmids were mixed in a 1.5ml 
microcentrifuge tube. Using the Neon electroporation system with settings 1400V, 10ms and 3 
pulses, the cells and plasmid mixture were electroporated. The electroporated suspension was then 
dispersed over a 10cm culture plate prepared with MEFs and mESC culture media. After 24 hours, 
positive selection began with 48 hours exposure to puromycin. After 48 hours in puromycin 
selection the cells were changed to neomycin selection. Cells were left in neomycin selection until 
70% confluent and ready for picking. 
 
Picking transfected embryonic stem cell colonies 
After selection, single healthy mESC colonies were picked. The term ‘picked’ means to you 
remove a single colony with as little MEFs as possible. Colonies were picked using 20µl filter 
pipette tip set to 10µl under phase microscope and transferred into 96 WP holding 30µl of trypsin 
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in each well. After picking, the 96WP was incubated for 5 mins at 37°C before neutralising the 
trypsin by adding 70µl of mESC culture media into each well. Picked colonies in the 96WP were 
then resuspened by pippeting up and down and transferred to a 96WP lined prepared with MEFs 
and 100µl of mESC culture media in each well. After 24 hours the media in the 96WP was changed 
to neomycin half selection. 
 
1:3 splitting of a 96 well plate 
Once picked mESC clones became confluent the 96WP was split into three 96WPs. Media was 
removed from the original 96WP and washed twice with PBS. 30µl of trypsin 2X+G was added 
to each well and incubated for 8 mins before neutralizing with 150ul of mESC culture media. 
Three 96WPs were then prepared to collect the cells. 150µl of mESC culture media was added to 
each well in two 96WPs lined with MEFs and one 96WP lined with 0.1% gelatin. Once the 
collection plates were prepared, 60µl of the 180µl of cell suspension was split into each well of 
the three 96WPs. After 24 hours, the media was changed to neomycin half selection. 
 
Freezing a 96 well plate  
To freeze a 96WP, the media was aspirated off and wells washed twice with 150µl of PBS. 30ul 
of trypsin 2X+G was then added to each well and incubated for 8 mins. The tryspsin was then 
neutralised with 70µl of cell culture media. 100µl of Freeze mix was then added to each well. Each 
well was covered with 50µl of mineral oil. The plate was sealed with parafilm and placed into a 
Styrofoam box layered with wet ice. The box was then stored at -80°C. 
 
Freezing cyrovials of positive clones 
Media was aspirated off cells in the culture flask and cells were washed twice with a suitable 
amount of PBS. Trypsin 2X+G was added and incubated for 8 mins at 37°C before neutralizing 
with mESC culture media. Cells were then resuspend before centrifuging for 5 mins at 1000rpm. 
The supernatant was aspirated off and the pellet of cells was resuspended in mESC culture media 
(250µl per cyrovial). To each cryovial 250µl of freeze mix and 250µl of the cell suspension was 
added. Cyrovials were placed into ‘Mr Frosty’ freezing vessel and stored at -80°C. 
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Thawing positive clones from 96 well plate 
A 24WP with MEF feeder layer was prepared with 1ml of prewarmed mESC culture media. The 
96WP was thawed inside a waterproof bag in a 37°C water bath. Once thawed, a 200µl pipette, set 
to 180µl was plunged into the well of the confirmed clone to be thawed. With the tip of the pipette 
below the mineral oil, the cells were extracted. The entire 180µl was transferred into the prepared 
24WP and cultured until ready to passage. 
 
Thawing positive clones from cyrovials 
The cryovial was quickly thawed in a 37°C water bath. Once a small piece of ice was visible, 0.5ml 
of prewarmed mESC cell culture media was added to complete the thaw. The entire contents of 
the thawed cryovial was added to a 15ml falcon tube, along with an additional 4ml of mESC cell 
culture media. The falcon tube was centrifuged at 1000rpm for 5 mins. The supernatant was 
discarded and cell pellet was resuspended in a suitable volume of media for the intended purpose. 
 
TAT-Cre recombinase treatment of embryonic stem cell 
Once positive clones in 96WP reached 40% confluence the media was refreshed and 6µM of TAT-
Cre recombinase was added to each well. The plate was incubated overnight before aspirating off 
the TAT-Cre containing media and replacing with fresh mESC culture media. 
3.3 Mouse and embryo procedures 
The care and maintenance of all mice used in this study was undertaken by trained animal 
technicians at the WTCHG. All of the procedures described in this section were performed by 
trained transgenic technologist in accordance with the UK Home Office Animals (Scientific 
Procedures) Act 1986 and the University of Oxford ethics committee. The methodologies 
described in this section are intended to provide a concise overview. For further details, please 
refer to ‘Manipulating the Mouse Embryo’ by Behringer et al. (2014). 
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3.3.1 Superovulation 
In preparation for blastocyst harvesting, Bl6-albino females were superovulated by injecting each 
mouse with 3.75 IU of pregnant mare's serum gonadotropin (PMSG) followed by the same dose 
of human chorionic gonadotropin (hCG) 46 to 48 hours later. Both hormones were administered 
by intraperitoneal injection with a 25 gauge syringe. After administration of hCG, each female was 
placed into a cage with one stud male. The following morning, superovulated females were 
checked for vaginal plugs. 
	
3.3.2 Mouse culling protocol 
Mice were culled by cervical dislocation when required. Their necks were humanely broken by 
quickly applying firm pressure at the base of the skull, while at the same time pulling the tail 
backwards. 
 
3.3.3 Blastocyst harvesting 
Superovulated and plugged females were left for 2.5 days post cortium before culling. The 
abdominal cavity was immediately opened and the reproductive organs located. A cut was then 
made between the oviduct and the ovary, keeping the uterotubal junction intact. The uterus was 
removed and placed into M2 media with HEPES. Blastocysts were then flushed through the 
infundibulum and collected using an embryo handling pipette. Blastocysts were rinsed and kept in 
KSOM media overnight at 37°C. The following day healthy blastocyst were microinjected with 
confirmed Fbxw7(R482Q) mESCs. 
 
3.3.4 Blastocyst microinjection 
‘Black coat’ Fbxw7(R482Q) confirmed mESCs were injected into ‘white coat’ Bl6-albino 
blastocysts. Successful integration of the black coat Fbxw7(R482Q) targeted mESCs will yield 
black and white chimeric pups. See Figure 3.1 for pictures from blastocyst microinjection process. 
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Figure 3.1 Blastocyst microinjection process. (a) The injection needle collects healthy and 
undifferentiated mouse embryonic stem cells (ESCs) and are positioned near the pipette tip. A 
blastocyst is then immobilised on a holding pipette so that the inner cell mass is at 6 o’clock. (b) and 
(c) The needle is gentle pushed into the blastocyst cavity. (d) and (e) 10 to 12 mESCs are slowly 
released into the blastocyst cavity. (f) The needle is slowly withdrawn and the blastocyst walls collapse 
back together. 
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3.3.5 Blastocyst uterine transfer 
A CD1 pseudo pregnant foster mother was anesthetized with inhaled isoflourane at 4% for 
induction and 2% for maintenance. Oxygen flow was set between 400 to 500 ml per min. A transfer 
pipette was loaded with blastocysts previously injected with targeted mESCs. The foster mother 
was placed on her abdomen and a small 1 cm incision was made in her back. Through the incision 
the uterus was located and a small hole was made in the uterine wall using a 25 gauge needle. 
After removing the needle, the transfer pipette, loaded with the blastocysts was placed into the 
hole and approximately 15 blastocysts were expelled. The reproductive organs were then 
relocalised and the body wall sutured and wound clips added. Each foster mother was administered 
with buprenorphine to assist in relieving any post-surgical pain.  
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4 Results 
4.1 gRNA design 
The gRNA was designed using the CRISPOR online tool (Haeussler et al., 2016) and had the 
predicted characteristics shown in Table 4.1. It’s important to note that the gRNA target site was 
not present in the Fbxw7 donor plasmid to prevent recurrent cleavage after HDR integration. The 
expected gRNA target site within the mouse genome (GRCm38/mm10) is depicted below in 
Figure 4.1. 
 
Table 4.1 gRNA characteristics generated using CRISPOR online tool.  
gRNA Primer (cDNA) PAM Specificity Score 
Predicted 
efficiency 
Off-targets for 
mismatches 
0 1 2 3 4 
5’-GGGACCCTGGTTCCACCTCA-3’ AGG 72 51 0 0 1 15 125 
 
 
 
Figure 4.1 gRNA target site. The designed gRNA is expected to produce a double stranded DNA 
break (DSB) in intron 11 of Fbxw7 gene on chromosome 3 in the mouse genome. 
4.2 Validation of cCRISPR expression plasmid 
Annealed gRNA primers were subcloned into the CRISPR expression plasmid using BbsI 
restriction sites. A successful cloning protocol removes the BbsI recognition sites (Figure 4.2). To 
validate the cCRISPR expression plasmid, the plasmid was digested with BbsI and HindIII 
3’-GGTCTGACACGGTACCTTGGAACTCCACCTTGGTCCCAGGGATTCAGTCCCTTGGTTAGTCTACCGGTCAACTAGAGG-5’
5’-CCAGACTGTGCCATGGAACCTTGAGGTGGAACCAGGGTCCCTAAGTCAGGGAACCAATCAGATGGCCAGTTGATCTCC-3’
PAM
Expected	DSB	
✂ ️
Fbxw7	on	chromosome	3	(163931	bp and	14	exons)
CRISPR	gRNA	Target	Site
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
141312111
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restriction enzymes. The location of these restriction sites in the CRISPR expression plasmid can 
be seen in Figure 2.1. The plasmid digestion was run on a gel electrophoresis (GE) which offered 
preliminary validation of a successful cloning protocol (Figure 4.3). Confirmation of the annealed 
gRNA primers in the cCRISPR expression plasmid was obtained by Sanger sequencing (Figure 
4.4). 
 
 
Figure 4.2 Cloning of annealed gRNA primers into BbsI restriction sites in CRISPR expression 
plasmid. Successful cloning disrupts BbsI recognition sites, which are highlighted in grey. 
 
 
 
Figure 4.3 GE from digestion of CRISPR expression plasmids with BbsI and HindIII restriction 
enzymes. The control plasmid produced the predicted three bands at 22, 4687 and 5534 bp (22 bp 
band is not visible in this image). The cCRISPR expression plasmid produced only one band at 10243 
bp, which indicates the removal of the BbsI recognition sites and successful integration of the 
annealed gRNA primers. 
U6	Promoter
5’-GAAACACCGGGTCTTCGAGAAGACCTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC-3’
3’-CTTTGTGGCCCAGAAGCTCTTCTGGACAAAATCTCGATCTTTATCGTTCAATTTTATTCCGATCAGGCAATAGTTGAACTTTTTCACCGTGGCTCAGCCACG-5’
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BbsI BbsI
CACCGGGACCCTGGTTCCACCTCA
CCCTGGGACCAAGGTGGAGTCAAA
||||||||||||||||||||
CRISPR	expression	plasmid
5’-GAAACACCGGGACCCTGGTTCCACCTCAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC-3’
3’-CTTTGTGGCCCTGGGACCAAGGTGGAGTCAAAATCTCGATCTTTATCGTTCAATTTTATTCCGATCAGGCAATAGTTGAACTTTTTCACCGTGGCTCAGCCACG-5’
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tracrRNA (82	bp)Unique	 crRNA	(20	bp)
Transcribed	as	gRNA
Subcloning of	annealed	gRNA	primers	
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Figure 4.4 Sanger sequencing of cCRISPR expression plasmid confirmed the annealed gRNA 
primers had been successfully ligated into BbsI restriction sites. The integrated gRNA primer reads 
5’-GGGACCCTGGTTCCACCTCA-3’. 
4.3 Testing gRNA cutting efficiency in mouse melanoma cells 
The gRNA cutting efficiency was tested in mouse melanoma cells. Cells were separately lipofected 
with cCRISPR expression plasmid and GFP expression plasmid. Cells lipofected with GFP 
expression plasmid were used to assess the transfection efficiency. Figure 4.5 illustrates the 
lipofection protocol was highly effective with numerous cells expressed GFP two days after 
transfection.  
 
 
Figure 4.5 Mouse melanoma cells two days after lipofection with GFP expression plasmid. (a) Cells 
under phase microscopy. (b) Image 'a' merged with an image taken with fluorescein isothiocyanate 
(FITC) filter of the same field. Extensive expression of GFP indicates a successful lipofection protocol. 
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Mouse melanoma cells lipofected with the cCRISPR expression plasmid will express SpCas9 and 
the gRNA targeting the Fbxw7 locus (Figure 5.1). Once confluent, transfected cells were lysed 
and DNA extracted. The DNA from both targeted and control melanoma cells were separately 
sequenced across the gRNA target site. A TIDE analysis was performed using the qualitative 
sequence trace data from the two standard capillary sequencing reactions. The TIDE software 
calculated the total cutting efficiency of the gRNA to be 33.2% (Figure 4.7a). The efficacy of 
gRNA was further supported in the quality assurance graph depicted in Figure 4.7b.  This graph 
illustrates that aberration of >20% between the control and Fbxw7 targeted sequences commences 
proximal (12 bp upstream) to the expected gRNA cut site.  
 
 
Figure 4.6 TIDE analysis results from gRNA testing in mouse melanoma cells. (a) The type and 
percentage of indels at gRNA target site. 27.3% of Fbxw7 targeted DNA had a 1 bp deletion, whilst 
3.4% had a 1 bp insertion. The gRNA had a predicted cutting efficacy of 33.2%. (b) Aberrance 
between the control and Fbxw7 targeted sequences. Sequence aberration > 20% between the control 
and targeted DNA commences l2 bp upstream from expected gRNA cut site. 
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4.4 Screening of embryonic stem cells for positive clones 
Sufficient cutting efficiency in mouse melanoma cells allowed the study to progress to gene 
targeting in mESCs. mESCs were electroporated with the cCRISPR expression plasmid and the 
Fbxw7 donor plasmid in an attempt to induce cellular repair of CRISPR-mediated DSBs via HDR. 
After selection, picking and expansion, 22 mESC clones remained that were screened for target 
vector integration via a series three PCRs. Figure 4.7 shows the expected PCR product sizes in 
positive clones using each of the three PCR primer pairs (PPs) employed. 
 
 
Figure 4.7 Screening for Fbxw7 construct integration. Expected PCR product sizes using primer 
pairs (PPs) 1, 2 and 3 in positive Fbxw7 targeted clones. PP1 (red), PP2 (pink) and PP3 (blue) have 
anticipated PCR product sizes in positive clones of 452, 7225 and 7445 bp, respectively.  
 
4.4.1 Preliminary screening 
Preliminary clone screening was performed using a PCR with PP1 to detect for the presence of the 
Fbxw7 construct. This screening provided no information on the genomic location of the donor 
construct. The variation between the PCR product sizes of the WT (640 bp) and the targeting 
construct (452 bp) was used to detect the presence of the Fbxw7 targeting construct (Figure 4.8). 
Of the 22 clones screened, 12 clones were preliminarily positive for construct integration and 9 
clones were moved on for further screening (Figure 4.9). Furthermore, it should be noted that the 
absence or extremely weak WT signal in 5 of the 12 preliminarily positive clones is suggestive of 
a homozygous integration within those clones. 
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Figure 4.8 PCR product sizes of wild type clones (WT; 640 bp) and Fbxw7 targeted clones (452 bp) 
when amplified using primer pair 1 (PP1). 
 
 
 
Figure 4.9 GE from preliminary PCR screening with primer pair 1 (PP1). Fbwx7 targeting construct 
produces a 452 bp band, whilst the wild type (WT) band is at 640 bp. Clones denoted with an asterisk 
were moved on for further screening. C is a water control.  
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4.4.2 Screening for 3’ integration 
A long range PCR was performed using PP2 to confirm 3’ integration of the targeting construct in 
the 9 preliminary positive clones. Positive clones produce a PCR product of 7225 bp (Figure 4.10), 
whilst negative clones have no amplified PCR product. The results of the screening can be seen in 
the GE image in Figure 4.11. 6 of the 9 clones screened had strong positive bands at 7225 bp; 
however, for efficiency only 4 were progressed to the next stage of screening. 
 
 
Figure 4.10. PCR product size in targeted clones with positive 3’ construct integration using primer 
pair 2 (PP2). Positive clones will amplify a 7225 bp product and wild type clones will have no 
amplified PCR product.  
 
 
 
Figure 4.11 GE from PCR screening with primer pair 2 (PP2) to confirm 3' construct integration. 
Successful 3’ integration produces a single band at 7225 bp. Wild type (WT) clones have no PCR 
product. Clones denoted with an asterisk were moved on for further screening. C is a water control. 
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4.4.3 Screening for 5’ integration 
To confirm 5’ construct integration in the 4 putative positive mESC clones, a PCR was performed 
using PP3. Positive clones have a PCR product of 7445 bp (Figure 4.12). The results of the GE 
shown in Figure 4.13 confirmed 5’ integration in all 4 clones. 
 
 
Figure 4.12. PCR product size in positive clones with 5’ construct integration using primer pair 3 
(PP3). Positive clones will amplify a PCR product of 7445 bp and wild type clones will have no 
detectable PCR product.  
 
 
Figure 4.13 GE from PCR screening with primer pair 3 (PP3) to confirm 5' construct integration. 
Successful 5’ integration produces a single band at 7445 bp. All 4 clones screened were confirmed for 
5’ construct integration. Wild type (WT) clones have no PCR product. C is a water control. 
4.5 TAT-Cre treatment of confirmed embryonic stem cell clones 
After confirming 5’ and 3’ construct integration, the Cre-dependent conditional KI was tested for 
functionality. All four positive mESC clones were treated with TAT-Cre recombinase to induce 
recombination between loxP sites. Successful Cre/loxp recombination will lead to a 3553 bp 
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deletion (Figure 4.12). TAT-Cre treated clones were viewed under epifluorescence microscopy 
with DAPI filter to visualise conditional expression of the CFP reporter gene. CFP is only 
expressed after Cre/loxp recombination and excision of the floxed STOP cassette. Images from the 
microscopy session can be seen in Figure 4.14. TAT-Cre treated clones had faintly increased 
fluorescence compared to non-treated clones. 
 
As the images from the microscopy session were inclusive, TAT-Cre treated clones were lysed 
and DNA extracted for a PCR screening protocol. TAT-Cre treated cloned were screened were 
PCR amplified using PP3. Successful recombination between loxP site results in a 3553 bp 
deletion and consequently a PCR product of 3892 bp (Figure 4.12). The GE results shown in Figure 
4.13 confirmed loxP recombination occurred in proportion of the cells in all four clones. Within 
the GE image strong bands are evident at both 7445 bp (no loxP recombination) and 3892 bp (loxP 
recombination). 
 
 
 
Figure 4.12 PCR product sizes in positive clones using primer pair 3 (PP3) both with (+Cre; 3892 bp) 
and without (-Cre; 7445 bp) TAT-Cre treatment. Wild type clones have no PCR product. 
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Figure 4.13 GE from PCR screening with primer pair 3 (PP3) of TAT-Cre treated mESC clones. 
Screen was to confirm Cre/loxP recombination events. All four clones treated with TAT-Cre 
generated a 3892 bp in a proportion of cells. This indicates recombination of the loxP sites was 
successful in a proportion of cells in all four clones. Wild type (WT) clones have no PCR product. C 
is a water control.  
4.6 Blastocyst microinjection and offspring 
Four positive mESC clones were confirmed at the completion of screening and functional testing. 
These clones were identified as D01, E01, D02 and E02. Each of these clones had stable and 
functional Cre-dependent conditional KI construct integration within intron 11 of the Fbxw7 gene. 
Frozen copies of two confirmed ‘black coat’ mESC clones (D01 and E01) were thawed and used 
for microinjection into ‘white coat’ Bl6-albion blastocysts. Injected blastocysts were transferred 
into CD1 foster mothers. The results of the microinjection session and the offspring are 
summarised in Table 4.2. Chimeric males from the litters were kept for further breeding. The 
percentage chimerism of the 10 males born was evaluated by visual assessment of the coat colour. 
Unfortunately, due to institutional policy at the WTCHG, no photography of experimental animals 
is permitted.  
 
Table 4.2 Summary of the blastocyst microinjection session and the resulting litters. 
mESC 
clone 
Blastocysts 
injected 
CD1 foster 
mothers Mice born Males born 
Chimerism of males 
(%) 
D01 36 2 5 4 95, 80, 80, 50 
E01 38 2 11 6 95, 80, 80, 50, 0, 0 
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Figure 4.14 Epifluorescence microscopy of TAT-Cre treated clones. Each of the four positive clones (D01, D02, E01 and E02) was treat with 
(+Cre) and without (-Cre) TAT-Cre. Images were taken under phase contrast, and epifluorescence microscopy using a DAPI filter. All 
TAT-Cre treated clones have evidence of increased florescence due to CFP expression.
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5 Discussion 
This study sought to develop a cancer mouse model harbouring a 5.5 kb conditional KI within 
intron 11 of the Fbxw7 gene. The targeting construct used in this study contained a Cre-dependent 
conditional missense point mutation (R482Q) within exon 12 of Fbxw7. This point mutation is 
present in a diverse range of human cancers, including breast, lung and colorectal cancer (Babaei-
Jadidi et al., 2011; Davis et al., 2011). A CRISPR/Cas9-meditated gene targeting strategy was used 
to generate mESCs for blastocyst microinjection. Direct gene targeting in mouse zygotes was not 
feasible due to the size and complexity of the Fbxw7 donor plasmid required to generate this large-
scale conditional KI (17631 bp; Figure 2.2). Direct microinjection of donor plasmids into mouse 
zygotes have very low rates of integration, typically, 10 to 30% of zygotes carry the desired 
construct (Yang, Wang, & Jaenisch, 2014). As a CRISPR/Cas9-meditated gene targeting approach 
was employed, a gRNA targeting intron 11 in Fbxw7 was designed (Figure 4.1). On examination 
of the Fbxw7 target site it was evident that there were limited gRNA options that would not cleave 
of the Fbxw7 donor plasmid, whilst meeting the PAM requirements of SpCas9 and having an 
adequate predicted cutting efficiency. After systematic consideration, a gRNA was selected with 
a predicted cutting efficiency of 51 out of 100 at the Fbxw7 locus. This was calculated using the 
method developed by Fusi et al. (2015) and warranted further investigation to ensure sufficient 
cutting efficiency of the selected gRNA. 
To experimentally investigate the cutting efficiency of the selected gRNA it was the tested in 
mouse melanoma cells. gRNA primers were subcloned into a CRISPR expression plasmid and the 
cloned plasmid was validated by restriction digestion before being confirmed by sequencing 
(Figure 4.2, 4.3 and 4.4). Melanocytes were then separately lipofected with the cCRISPR 
expression plasmid and a GFP expression plasmid. GFP expression in transfected cells confirmed 
an effective transfection protocol (Figure 4.5). Mouse melanoma cells successfully lipofected with 
the cCRISPR expression plasmid will express the unique gRNA and SpCas9, which, once 
complexed are capable of generating DSBs at the Fbxw7 target site in intron 11 (Figure 5.1). As 
no repair template was provided, CRISPR/Cas9-mediated DSBs are favourable repaired by the 
error prone NHEJ pathway, which often leaves indel mutations. To assess the frequency of indel 
mutations and consequently the cutting efficiency of the gRNA, a TIDE analysis was undertaken 
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using the software package designed by Brinkman et al. (2014). To do this, DNA was extracted 
from pools of CRISPR targeted melanocytes and non-targeted control melanocytes. The two DNA 
samples were separately sequenced across the gRNA target site. The quantitative trace data from 
the two Sanger sequencing reaction was then used by the TIDE software to determine the total 
cutting efficiency of the gRNA to be 33.2% (Figure 4.6a). Previous gRNA efficiencies measured 
at the WTCHG indicated this was sufficient to progress to gene targeting in mESCs. The TIDE 
software also generated a quality assurance graph that indicated that aberrations >20% between 
the control and Fbxw7 targeted sequences originate proximal to the expected gRNA cut site 
(Within 12 bp; Figure 2.5b).  
 
Figure 5.1 Cloned CRISPR (cCRISPR) expression plasmid. In mammalian cells this plasmid 
expresses the essential components for CRISPR/Cas9 gene targeting. The CRISPR expressed 
components are the unique gRNA and SpCas9 mRNA for translation into SpCas9 protein. Within 
this project, complexing of the gRNA and SpCas9 leads to cleavage at Fbxw7 target site in intron 11. 
 
Although the gRNA efficiency was evaluated in the melanoma cells, the specificity of the gRNA 
was not examined in vitro. Perhaps the greatest concern regarding CRISPR/Cas9 is the issue of off 
target effects. A number of studies in mammalian cells have documented off target mutations 
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occurring at significant rates at sites with sequence similarity to the on target sites (Cho et al., 
2014; Fu et al., 2013; Hsu et al., 2013). Off target effects could confound phenotypic analyses of 
the resulting Fbxw7R482Q mouse model. It has been demonstrated that, although each nucleotide 
within the 20 nt crRNA segment of the gRNA contributes to overall SpCas9 specificity, single 
mismatches are often well tolerated, and several mismatches can also be tolerated depending on 
their location within crRNA sequence and the context within the genome (Hsu et al., 2013; 
Pattanayak et al., 2013). Experimental protocols for screening off target effects are laborious, 
costly and time consuming, and is not yet a routine procedure for CRISPR/Cas9 GM mouse 
production. Instead an in silico based approach for determining off target potential of the gRNA 
was employed in this study. Within the mouse genome (GRCm38/mm10) the designed 20 nt 
crRNA portion of the gRNA had no additional target sites with 0 or 1 nt mismatches. However, 
for crRNA mismatches of 2, 3 and 4 nt there were 1, 15 and 125 off-target sites, respectively (Table 
4.1). These computational results suggested the gRNA had minimal potential for off target effects 
in the mouse genome.  
 
The optimisation and validation gRNA design is critical for reducing off target potential, however, 
alternative methods to improve the specificity of CRISPR/Cas9 have been developed. One strategy 
is to use different Cas9 systems, such as N. meningitides, which can offer better targeting 
specificity by virtue of its longer crRNA (24 nt for N. meningitidis) and longer PAM sequence (5’-
NNNNGATT for N. meningitides; Hou et al., 2013). Another strategy has been to use a modified 
version of SpCas9 that can only introduce a single-strand nick at the target site, rather than a DSB. 
Use of a pair of ‘nickase’ Cas9 complexes with binding sites on opposite strands of the target 
sequence can produce the equivalent of a DSB with 5’ overhangs. At an off-target site, a single-
strand nick would be repaired by a different mechanism, known as the base excision repair 
pathway, which is much less likely to leave indel mutations. Since the likelihood of two nickases 
binding nearby each other elsewhere in the genome is very low, the off target mutation rate is 
greatly reduced. Indeed, testing of this nickase systems in mammalian cells has demonstrated up 
to a threefold reduction in off target activity with only a slight reduction in on target efficacy (Cho 
et al., 2014; Ran et al.). 
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After verifying the efficiency and specificity of the selected gRNA, the study was progressed to 
gene targeting in mESCs. For this, the cCRISPR expression plasmid and Fbxw7 donor plasmid 
were electroporated in mESCs. The simultaneous transfection of the cCRISPR expression plasmid 
and the Fbxw7 donor plasmid was aimed at inducing mESCs to repair the CRISPR/Cas9-mediated 
DSB via HDR and thus copy the targeting construct into the break site. Figure 5.2 shows a 
schematic diagram of CRISPR/Cas9-mediated HDR using the Fbxw7 donor plasmid as a template. 
As the transfected cCRISPR expression plasmid contained a puromycin resistance gene, and the 
Fbxw7 donor plasmid was designed with a neomycin resistance gene and diphtheria toxin A 
cassette located outside the homology arms, this allowed for both positive and negative selection 
in transfected mESCs. After eight days of selection, 22 mESC clones were picked and expanded. 
Of the 22 clones, 4 were confirmed for 5’ and 3’ construct integration by series of three PCR 
screening protocols. However, PCR screening approaches cannot detect concurrent random 
integration and, therefore, full characterization requires Southern blotting (Wang et al., 2015). 
Although highly recommended, Southern blotting was not performed in this study. This decision 
was made with the foresight that 2 of the 4 clones will be used for blastocyst microinjection and 
all established mice lines undergo a complete characterization.  
 
Figure 5.2 CRISPR/Cas9-medaited gene targeting with Fbxw7 donor plasmid. SpCas9 and gRNA 
are expressed from the cCRISPR expression plasmid. A complex between gRNA and SpCas9 is 
formed which generates a DSB at the target site. The Fbxw7 donor plasmid then induces the cell to 
repair the DSB via HDR and thus copy’s the 5.5 kb conditional knock-in construct into the cut site. 
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The targeting construct used in this study took advantage of a Cre-dependent conditional KI 
system. Once integrated, this construct design will ultimately allow investigators to study the 
Fbxw7(R482Q) point mutation in specific cell lineage or at a specific developmental stage. The 
conditional KI system used in the Fbxw7 donor plasmid is known as the ‘minigene’ method 
(Figure 1.6b). The minigene method in the conditional KI construct contains a WT Fbxw7 
minigene (an intronless gene segment that contains exon 12, 13 and 14) and a STOP cassette, 
which are collectively floxed. Directly downstream from the floxed minigene system is the mutant 
Fbxw7(R482Q) allele and a CFP reporter gene. In the presence of Cre recombinase, recombination 
between the loxP sites will occur, resulting in excision of the floxed 3.5kb DNA sequence 
containing the WT Fbxw7 minigene and STOP cassette (Figure 5.3).  Following recombination of 
the loxP sites, the mutant Fbxw7(R482Q) allele and a CFP report gene will be expressed from 
their natural promoter. By including the CFP reporter gene in the construct it allows scientists to 
visually identify cells that are expressing the conditional mutant Fbxw7(R482Q) allele.  
 
Figure 5.3 Fbxw7 conditional knock-in construct, with and without Cre recombination. 
Recombination of the loxP sites results in 3553 bp deletion, which includes the WT Fbxw7 minigene 
and STOP cassette that prevent expression of the mutant Fbxw7(R482Q) and CFP reporter gene. 
 
To test the functionality of the conditional KI system in the four positive mESC clones, TAT-Cre 
recombinase was added to cells at 40% confluent. Once confluent, TAT-Cre treated clones were 
viewed under an epifluorescence microscope using a DAPI filter to visualise CFP expression. The 
images obtained from the microscopy session showed faint evidence of increased fluorescence 
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from CFP expression in TAT-Cre treated cells (Figure 4.14). To improve these findings, 
optimization of the TAT-Cre treatment protocol may increase CFP expression. Additionally, the 
use of a confocal fluorescence microscope as opposed to a standard epifluorescence microscope 
may allow for easier detection of CFP. As the microscopy session offered inclusive results, the 
functionality of the conditional KI system in the TAT-Cre treated clones required further 
investigation. To do this TAT-Cre clones were lysed and DNA extracted. Using a PCR based 
approach it was confirmed that the predicted 3.5 kb DNA sequence had been deleted from a 
proportion of cells in all four TAT-Cre treated clones (Figure 4.13). This indicated that Cre-
mediated recombination between the loxP sites had occurred. These findings confirmed that the 
Cre-dependent conditional KI system was functional in all four confirmed mESC clones. 
 
Following successful screening and functional testing, two of the four confirmed mESC clones 
(D01 and E01) were thawed from frozen copies and prepared for blastocyst microinjection. The 
positive mESCs were developed on a male ‘black coat’ JM8.F6 mESC background and injected 
into ‘white coat’ Bl6-albino blastocysts before being transferred into CD1 fosters mothers. Male 
mESCs were used to favour the development of male offspring, which are beneficial for future 
breeding. Successful integration of mESCs into the inner cell mass of the blastocysts results in 
black and white chimeric pups. The desired outcome was to generate germline competent chimeric 
males for germline transmission. Four litters were produced with a total of 8 chimeric males born 
that ranged in chimerism from 50 to 95% (Table 4.2). The percentage black coat colour was used 
to estimate the contribution of the mESC to the mice. However, it should be noted that coat colour 
does not fully reflect the injected mESCs contribution to the germ cells (Carstea et al., 2009). 
Currently, two 95% chimeric males are set for mating with white albino females in the hope of 
generating heterozygous Fbxw7R482Q (F1) offspring (Figure 5.4). Germline transmission of the 
mESC derived genes will result in black pups due to dominant inheritance of the black coat colour. 
Once a breeding population is established the Tomlinson group at the WTCHG plans to cross the 
Fbxw7R482Q mice with Villin-Cre mice. Villin-Cre mice express Cre recombinase in villus and crypt 
epithelial cells of the small and large intestines. Crossing of the Fbxw7R482Q mice with the VIllin-
Cre mice will allow the Tomlinson group to study the role of the Fbxw7(R482Q) missense point 
mutation in the development of colorectal cancer.  
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Figure 5.4 Breeding scheme to generate heterozygous Fbxw7R482Q (F1) from chimeric males (F0). 
Future plans are to cross Fbxw7R482Q mice with Villin-Cre mice to study the role of the Fbxw7(R482Q) 
mutation in the development of colorectal cancer. Image was modified and adapted from Lodish et 
al. (2000). 
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6 Conclusion 
In summary, the application of CRISPR/Cas9 in mESCs remains the ‘gold standard’ for generating 
large-scale conditional KI mouse models. This study successfully employed a CRISPR/Cas9-
mediated gene targeting approach in mESCs to generate conditional KI chimeric male mice to be 
used for germline transmission. To limit off target effects and enhance productivity, the CRISPR 
gRNA used in this study was tested via combination of in vitro and in silico based methods to 
validate both efficiency and specificity. The construct integrated into CRISPR/Cas9 target site in 
intron 11 of the Fbxw7 gene was a 5.5 kb Cre-dependent conditional KI that harboured a missense 
point mutation (Fbxw7(R482Q)) in exon 12. Fbxw7(R482Q) is found in a diverse range of human 
cancers. The targeting construct also included a CFP reporter gene to track expression of the 
mutant Fbxw7 allele. Following PCR based screening and functional testing of the targeted 
mESCs, two confirmed clones were microinjected into WT blastocysts. From the resulting four 
litters, eight chimeric males were born with up to 95% chimerism based on coat colour. Two 95% 
chimeric males are currently set for mating WT females in the hope of gaining germline 
transmission of the mESC derived genes. Successful transmission will generate heterozygous 
Fbxw7R482Q mice. The Tomlinson group at the WTCHG plans to cross the Fbxw7R482Q mouse model 
with Villin-Cre transgenic mice. This will enable the group to study the role Fbxw7(R482Q) point 
mutation in development of colorectal cancer. 
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Appendices 
Appendix A – Function of plasmid features 
Table A.1 Function of CRISPR expression plasmid features 
Plasmid features Function 
E. coli Replication Origin Origin for plasmid replication in E. coli during amplification. 
U6 Promoter Drives expression of gRNA and SpCas9 in mammalian cells. 
BbsI Restriction sites used to clone gRNA primers into plasmid. 
CAG Enhancer Enhances expression of SpCas9. 
Cas9 Encodes for Streptococcus pyogenes CRISPR associated protein 9 
(SpCas9), which is a RNA-guided DNA endonuclease. 
BGH Poly Terminator Bovine growth hormone polyadenylation, which is a mammalian 
transcription termination sequence. 
PGK Promoter and Puro 
Resistance 
Phosphoglycerate kinase promoter that drives expression of 
puromycin resistance gene in mammalian cells. 
Ampicillin Resistance Confers ampicillin resistance to E. coli during plasmid amplification. 
 
Table A.2 Function of Fbxw7 donor plasmid features 
Plasmid feature Function 
E. Coli Replication Origin Origin for plasmid replication in E. coli during amplification. 
Ampicillin Resistance Confers ampicillin resistance to E. coli during plasmid amplification. 
5’ Homology Arm 2KB 5’ homology arm to induce HDR after DSB by SpCas9. 
Lox5171 The active sites for Cre recombinase, which recombines the pair of 
loxP sites in the construct. 
WT-Fbxw7 Wild type version of Fbxw7. 
PGK Promoter Phosphoglycerate kinase promoter to drive expression of neomycin 
resistance in mammalian cells. 
NEO Confers neomycin resistance in mammalian cells. This cassette is 
used for positive selection. 
Stop and 3xPolyA Terminates further expression of the construct in mammalian cells. 
R482q – Fbxw7 Mutant version of Fbxw7 that contains the R482Q missense point 
mutation in exon 12. 
SCP – P2A Splits a single transcript into two for translation into two proteins. 
CFP – OPTI Optimised cyan fluorescent protein for detection of R482q – Fbxw7 
expression. 
PolyA Terminates transcription. 
3’ Homology Arm 6.5KB 3’ homology arm to induce HDR after DSB by SpCas9. 
Diphtheria Toxin A Encodes for diphtheria toxin A. This toxin is used as a negative 
selection cassette, preventing random integration into the genome by 
causing cell death 
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Table A.3 Function of GFP expression plasmid features 
Plasmid features Function 
CAG Promoter Strong synthetic promoter used to drive high levels of expression of 
eGFP in mammalian cells. 
eGFP Encodes for enhanced green fluorescent protein (GFP) 
Rabbit beta globin poly-A Terminates transcription. 
Origin of Replication (pUC) Origin for plasmid replication in E. coli during amplification. 
Ampicillin Resistance  Confers ampicillin resistance to E. coli during plasmid amplification. 
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Appendix B – Spectrophotometry results of plasmid purifications 
 
Figure B.1 NanoDrop™ spectrophotometry results for CRISPR expression plasmid purification. 
 
 
Figure B.2 NanoDrop™ spectrophotometry results for Fbxw7 donor plasmid purification. 
 
 
Figure B.3 NanoDrop™ spectrophotometry results for GFP expression plasmid purification. 
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Appendix C – Timeline scheme of cell culture procedures 
  
Figure C.1 Melanoma cell culture procedures and timeline. 
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Figure C.2 Embryonic stem culture procedures and timeline. 
 
 
